Skip to main content
      Two pioneering studies presented at ACR Convergence 2025 spotlight the potential of CAR-T cell therapies to transform treatment for systemic lupus erythematosus (SLE) and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and long-term disease remission.
      Saphnelo (anifrolumab) has been recommended for approval in EU by CHMP for systemic lupus erythematosus (on top of stand

      Dr. John Cush RheumNow

      2 weeks ago
      Saphnelo (anifrolumab) has been recommended for approval in EU by CHMP for systemic lupus erythematosus (on top of standard therapy) as a once-weekly pre-filled pen. Recommendation based on TULIP-SC Phase III trial. https://t.co/UurvtLNP7S https://t.co/xeKVdVYu3z
      Wondering whether rheumatology is the specialty for you?

      Dr Bryant England kicks off the clinical science #YearInReview

      Mrinalini Dey DrMiniDey

      2 weeks ago
      Wondering whether rheumatology is the specialty for you? Dr Bryant England kicks off the clinical science #YearInReview with an impressive overview of what a year in rheumatology looks like. New drugs, new devices, new disease names! 🤯 #ChooseRheumatology #ACR25 @RheumNow https://t.co/uLrNFPgeAn
      #Sjogren disease is here to stay.
      “The name has caught up to the science of SD and this can translate to better treat

      sheila RHEUMarampa

      2 weeks ago
      #Sjogren disease is here to stay. “The name has caught up to the science of SD and this can translate to better treatment outcomes for patients” - Dr. Bryant England #ACR25 @RheumNow https://t.co/M4r0XXkswv
      Basic Sci Year in Review:
      Dr. Anne Davidson discusses the potential pathologic link bet tryptophan, indole, I3S & I

      sheila RHEUMarampa

      2 weeks ago
      Basic Sci Year in Review: Dr. Anne Davidson discusses the potential pathologic link bet tryptophan, indole, I3S & IL-17 pathways. I3S induces epidermal thickening in mice and correlated with dse activity in patients with #psoriasis #ACR25 @RheumNow https://t.co/WNNbBBESQ3
      Rheum guidelines balance data & context.

      Beyond evidence, factors like cost, equity & feasibility shape recs.

      Jiha Lee JihaRheum

      2 weeks ago
      Rheum guidelines balance data & context. Beyond evidence, factors like cost, equity & feasibility shape recs. GRADE-ADOLOPMENT = global tool to adopt, adapt, or design local guidance for more rapid integration and with less $$$ @RheumNow #ACR25 #GlobalRheumSummitt https://t.co/Sfsqxsqpt4
      ACR Convergence 2025 will be kicking off with a Plenary Session by Michelle Petri (Abstract 0772: Redefining When to Biopsy the Kidney in Patients with SLE), which is a great place to kick off our coverage of the meeting. As part of a collaboration with the Accelerating Medicines Partnership, Petri and colleagues have given data to what many of us have long suspected: a biopsy threshold of 0.5g/d of proteinuria may be too high.
      Fatigue is one of the most disabling symptoms in psoriatic arthritis (PsA), yet its causes are often underexplored. At ACR 2025, Abstract #0549, a possible hidden contributor was studied: obstructive sleep apnea (OSA).
      We know that pre-RA is a definition that stands under a large umbrella, ranging from asymptomatic individuals with ACPA positivity to individuals with symptomatic pre-clinical synovitis. How can we predict the transition from the at-risk state to clinical RA outside the realm of clinical, conventional serological (RF/anti-CCP) or imaging (US/MRI synovitis) biomarkers?
      With increased disease awareness and more regular, accessible testing for anti-neutrophil cytoplasmic antibodies (ANCA), ANCA-associated vasculitis (AAV) has become an increasingly recognized clinical entity in rheumatologic practice. 
      RheumNow’s expanded coverage of the #ACR25 Annual Meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All

      Dr. John Cush RheumNow

      2 weeks ago
      RheumNow’s expanded coverage of the #ACR25 Annual Meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
      From Eye on Cytokine Storm- Decoding MAS by Dr Grant Schulert : “IL-18 is highly elevated in SJIa and other autoinflam

      Gabriela Martinez Zayas, MD MartinezZayasMd

      2 weeks 1 day ago
      From Eye on Cytokine Storm- Decoding MAS by Dr Grant Schulert : “IL-18 is highly elevated in SJIa and other autoinflammatory disorders…can amplify innate signaling as well as induce IFN-gamma”. @RheumNow #ACR2025 https://t.co/6e5yfeDepX
      🔥 Hot off the press

      Prof John Stone shares results from Phase 3 of REPLENISH, out only a few days ago, in which sec

      Mrinalini Dey DrMiniDey

      2 weeks 1 day ago
      🔥 Hot off the press Prof John Stone shares results from Phase 3 of REPLENISH, out only a few days ago, in which secukinumab met all primary endpoints in treatment of PMR. https://t.co/RlcQWybKrR #ACR25 @RheumNow https://t.co/ucNt2HxJpW
      Summary of updates in Vasculitis by Dr John Stone: 1. Anti-CD19 in IgG4Rd, 2. IL6 6R blockade in GCA/IL17i in PMR, 3. IL

      Gabriela Martinez Zayas, MD MartinezZayasMd

      2 weeks 1 day ago
      Summary of updates in Vasculitis by Dr John Stone: 1. Anti-CD19 in IgG4Rd, 2. IL6 6R blockade in GCA/IL17i in PMR, 3. IL5RA+ ritux in EGPA. CART in AAV? @RheumNow #ACR2025 https://t.co/HxPNRE98Vl
      ×